{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:30:37Z","timestamp":1787671837315,"version":"build-2736575974"},"reference-count":38,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015362","name":"Amicus Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015362","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ymgme.2026.109864","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T16:24:44Z","timestamp":1772641484000},"page":"109864","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Early enzyme replacement therapy in late-onset Pompe disease diagnosed by newborn screening"],"prefix":"10.1016","volume":"148","author":[{"given":"Laura E.","family":"Case","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Huggins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harrison N.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa D.","family":"Hobson-Webb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah R.","family":"McMechan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neelam","family":"Makhijani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Nading","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven A.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya S.","family":"Kishnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ymgme.2026.109864_bb0005","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1042\/bj0860011","article-title":"Alpha-glucosidase deficiency in generalized glycogenstorage disease (Pompe\u2019s disease)","volume":"86","author":"Hers","year":"1963","journal-title":"Biochem. J."},{"issue":"1","key":"10.1016\/j.ymgme.2026.109864_bb0010","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/ajmg.c.31322","article-title":"Toward deconstructing the phenotype of late-onset Pompe disease","volume":"160C","author":"Schuller","year":"2012","journal-title":"Am. J. Med. Genet. C: Semin. Med. Genet."},{"issue":"3","key":"10.1016\/j.ymgme.2026.109864_bb0015","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ymgme.2016.12.004","article-title":"The emerging phenotype of late-onset Pompe disease: a systematic literature review","volume":"120","author":"Chan","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2026.109864_bb0020","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.jpeds.2018.02.007","article-title":"Severe cardiac involvement is rare in patients with late-onset Pompe disease and the common c.-32-13T>G variant: implications for newborn screening","volume":"198","author":"Herbert","year":"2018","journal-title":"J. Pediatr."},{"issue":"2","key":"10.1016\/j.ymgme.2026.109864_bb0025","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ymgme.2018.08.009","article-title":"Early-onset of symptoms and clinical course of Pompe disease associated with the c.-32-13 T > G variant","volume":"126","author":"Herbert","year":"2019","journal-title":"Mol. Genet. Metab."},{"issue":"13","key":"10.1016\/j.ymgme.2026.109864_bb0030","doi-asserted-by":"crossref","first-page":"276","DOI":"10.21037\/atm.2019.06.48","article-title":"Variable clinical features and genotype-phenotype correlations in 18 patients with late-onset Pompe disease","volume":"7","author":"Alandy-Dy","year":"2019","journal-title":"Ann. Transl. Med."},{"issue":"2","key":"10.1016\/j.ymgme.2026.109864_bb0035","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1212\/01.wnl.0000252798.25690.76","article-title":"Broad spectrum of Pompe disease in patients with the same c.-32-13T->G haplotype","volume":"68","author":"Kroos","year":"2007","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.ymgme.2026.109864_bb0040","first-page":"89","article-title":"Extent, impact, and predictors of diagnostic delay in Pompe disease: a combined survey approach to unveil the diagnostic odyssey","volume":"49","author":"Lagler","year":"2019","journal-title":"JIMD Rep."},{"issue":"4","key":"10.1016\/j.ymgme.2026.109864_bb0045","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.pedneo.2013.03.009","article-title":"Pompe disease: early diagnosis and early treatment make a difference","volume":"54","author":"Chien","year":"2013","journal-title":"Pediatr. Neonatol."},{"issue":"6","key":"10.1016\/j.ymgme.2026.109864_bb0050","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.jpeds.2010.11.053","article-title":"Later-onset Pompe disease: early detection and early treatment initiation enabled by newborn screening","volume":"158","author":"Chien","year":"2011","journal-title":"J. Pediatr."},{"issue":"3","key":"10.1016\/j.ymgme.2026.109864_bb0055","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ymgme.2017.09.008","article-title":"Insight into the phenotype of infants with Pompe disease identified by newborn screening with the common c.-32-13T>G \u201clate-onset\u201d GAA variant","volume":"122","author":"Rairikar","year":"2017","journal-title":"Mol. Genet. Metab."},{"issue":"4","key":"10.1016\/j.ymgme.2026.109864_bb0060","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00415-016-8219-8","article-title":"Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis","volume":"264","author":"Schoser","year":"2017","journal-title":"J. Neurol."},{"issue":"12","key":"10.1016\/j.ymgme.2026.109864_bb0065","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/S1474-4422(21)00241-6","article-title":"Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial","volume":"20","author":"Diaz-Manera","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymgme.2026.109864_bb0070","series-title":"Package Insert","author":"LUMIZYME\u00ae(alglucosidase alfa)","year":"2010"},{"key":"10.1016\/j.ymgme.2026.109864_bb0075","series-title":"Package Insert","author":"NEXVIAZYME\u00ae(avalglucosidasealfa-ngpt)","year":"2021"},{"key":"10.1016\/j.ymgme.2026.109864_bb0080","series-title":"Package Insert","author":"POMBILITITM\u2122 (cipaglucosidase alfa-atga)","year":"2023"},{"key":"10.1016\/j.ymgme.2026.109864_bb0085","series-title":"Package Insert","author":"OPFOLDATM\u2122(miglustat)","year":"2023"},{"issue":"6","key":"10.1016\/j.ymgme.2026.109864_bb0090","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s10545-010-9201-8","article-title":"Long-term observational, non-randomized study of enzyme replacement therapy in late-onset glycogenosis type II","volume":"33","author":"Bembi","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"issue":"6","key":"10.1016\/j.ymgme.2026.109864_bb0095","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s00431-013-2258-2","article-title":"Enzyme replacement therapy in juvenile glycogenosis type II: a longitudinal study","volume":"173","author":"Deroma","year":"2014","journal-title":"Eur. J. Pediatr."},{"issue":"1","key":"10.1016\/j.ymgme.2026.109864_bb0100","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13023-016-0442-y","article-title":"Childhood Pompe disease: clinical spectrum and genotype in 31 patients","volume":"11","author":"van Capelle","year":"2016","journal-title":"Orphanet J. Rare Dis."},{"issue":"3","key":"10.1016\/j.ymgme.2026.109864_bb0105","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ymgme.2022.01.003","article-title":"Early clinical phenotype of late onset Pompe disease: lessons learned from newborn screening","volume":"135","author":"Huggins","year":"2022","journal-title":"Mol. Genet. Metab."},{"issue":"Suppl. 1","key":"10.1016\/j.ymgme.2026.109864_bb0110","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1542\/peds.2016-0280E","article-title":"Management of confirmed newborn-screened patients with Pompe disease across the disease spectrum","volume":"140","author":"Kronn","year":"2017","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2026.109864_bb0115","doi-asserted-by":"crossref","DOI":"10.1186\/2051-5960-2-2","article-title":"The value of muscle biopsies in Pompe disease: identifying lipofuscin inclusions in juvenile- and adult-onset patients","volume":"2","author":"Feeney","year":"2014","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.ymgme.2026.109864_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2026.109762","article-title":"Lessons from late-onset Pompe disease identified by newborn screening: a systematic review","author":"Boueri","year":"2026","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2026.109864_bb0125","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.cnp.2019.04.006","article-title":"Neuromuscular ultrasound in clinical practice: a review","volume":"4","author":"Gonzalez","year":"2019","journal-title":"Clin. Neurophysiol. Pract."},{"issue":"3","key":"10.1016\/j.ymgme.2026.109864_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2025.109237","article-title":"Quantitative muscle ultrasound as a window into disease progression in infantile-onset Pompe disease","volume":"146","author":"Makhijani","year":"2025","journal-title":"Mol. Genet. Metab."},{"issue":"11","key":"10.1016\/j.ymgme.2026.109864_bb0135","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.86821","article-title":"Durable and sustained immune tolerance to ERT in Pompe disease with entrenched immune responses","volume":"1","author":"Kazi","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymgme.2026.109864_bb0140","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2024.1309146","article-title":"Real-world outcomes from a series of patients with late onset Pompe disease who switched from alglucosidase alfa to avalglucosidase alfa","volume":"15","author":"Carter","year":"2024","journal-title":"Front. Genet."},{"issue":"1","key":"10.1016\/j.ymgme.2026.109864_bb0145","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/ajmg.c.31321","article-title":"Infantile Pompe disease on ERT: update on clinical presentation, musculoskeletal management, and exercise considerations","volume":"160C","author":"Case","year":"2012","journal-title":"Am. J. Med. Genet. C: Semin. Med. Genet."},{"issue":"5","key":"10.1016\/j.ymgme.2026.109864_bb0150","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1097\/01.gim.0000217789.14470.c5","article-title":"Physical therapy management of Pompe disease","volume":"8","author":"Case","year":"2006","journal-title":"Genet. Med."},{"issue":"9","key":"10.1016\/j.ymgme.2026.109864_bb0155","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.nmd.2015.07.002","article-title":"Homozygosity for the common GAA gene splice site mutation c.-32-13T>G in Pompe disease is associated with the classical adult phenotypical spectrum","volume":"25","author":"Musumeci","year":"2015","journal-title":"Neuromuscul. Disord."},{"issue":"5","key":"10.1016\/j.ymgme.2026.109864_bb0160","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1002\/mus.24437","article-title":"Correlation between quantitative whole-body muscle magnetic resonance imaging and clinical muscle weakness in Pompe disease","volume":"51","author":"Horvath","year":"2015","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.ymgme.2026.109864_bb0165","first-page":"38","article-title":"Recognition and management of motor delay and muscle weakness in children","volume":"91","author":"Lurio","year":"2015","journal-title":"Am. Fam. Physician"},{"issue":"1","key":"10.1016\/j.ymgme.2026.109864_bb0170","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2019-3449","article-title":"Promoting optimal development: identifying infants and young children with developmental disorders through developmental surveillance and screening","volume":"145","author":"Lipkin","year":"2020","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2026.109864_bb0175","first-page":"67","article-title":"Baseline urinary glucose tetrasaccharide concentrations in patients with infantile- and late-onset Pompe disease identified by newborn screening","volume":"19","author":"Chien","year":"2015","journal-title":"JIMD Rep."},{"issue":"1","key":"10.1016\/j.ymgme.2026.109864_bb0180","first-page":"94","article-title":"Quantitative whole-body magnetic resonance imaging in children with Pompe disease: clinical tools to evaluate severity of muscle disease","volume":"57","author":"Fernandes","year":"2021","journal-title":"JIMD Rep."},{"issue":"7","key":"10.1016\/j.ymgme.2026.109864_bb0185","article-title":"Efficacy of quantitative muscle ultrasound using texture-feature parametric imaging in detecting Pompe disease in children","volume":"21","author":"Chiou","year":"2019","journal-title":"Entropy Basel."},{"key":"10.1016\/j.ymgme.2026.109864_bb0190","article-title":"Muscle ultrasound in patients with late-onset Pompe disease identified by newborn screening","volume":"36","author":"Jackson","year":"2023","journal-title":"Mol. Genet. Metab. Rep."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719226001472?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719226001472?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:58:52Z","timestamp":1787669932000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719226001472"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1096719226001472"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2026.109864","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early enzyme replacement therapy in late-onset Pompe disease diagnosed by newborn screening","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2026.109864","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"109864"}}